| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
146,000,000 |
| Market
Cap: |
16.22(B) |
| Last
Volume: |
1,035,875 |
Avg
Vol: |
1,333,523 |
| 52
Week Range: |
$92.79 - $212.65 |
|
| Level
I Sector: |
Information Technology |
| Level
II Sector: |
Electronics |
| Level
III Sector: |
Scientific & Technical Instruments |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : 11.4 |
| Insider 6 Months : 11.4 |
| Insider 3/6 Months : 23.2 |
|
| Guru Rank Number : 691 |
| Guru Rank Value : 2.3 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Illumina is engaged in sequencing- and array-based solutions for genetic and genomic analysis. Co. provides whole-genome sequencing, genotyping, noninvasive prenatal testing (NIPT), and product support services. Using Co.'s services, customers can perform whole-genome sequencing projects and microarray projects (including large-scale genotyping studies and whole-genome association studies). Co. provides NIPT services through its partner laboratories that direct samples to Co. on a test send-out basis in its Clinical Laboratory Improvements Amendments-certified, College of Pathologists-accredited laboratory. Co. also provides support services to customers who have purchased its products.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
7,330 |
7,330 |
7,330 |
7,330 |
| Total Buy Value |
$991,672 |
$991,672 |
$991,672 |
$991,672 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
0 |
0 |
6,815 |
22,740 |
| Total Sell Value |
$0 |
$0 |
$1,357,080 |
$4,648,975 |
| Total People Sold |
0 |
0 |
2 |
3 |
| Total Sell Transactions |
0 |
0 |
5 |
17 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Flatley Jay T |
Director |
• • – |
2020-05-19 |
4 |
AS |
$342.34 |
$1,369,360 |
D/D |
(4,000) |
241,970 |
|
-4% |
|
| Samad Samer Abdul |
SVP and CFO |
• • – |
2020-05-18 |
4 |
AS |
$340.00 |
$461,380 |
D/D |
(1,357) |
5,235 |
|
-6% |
|
| Tousi Susan H |
SVP Product Development |
• • – |
2020-05-12 |
4 |
AS |
$325.00 |
$195,000 |
D/D |
(600) |
48,054 |
|
-16% |
|
| Ostadan Omead |
SVP Mktg, Prod & Strat Plan |
• • – |
2020-05-11 |
4 |
AS |
$315.13 |
$674,369 |
D/D |
(2,140) |
17,172 |
|
-16% |
|
| Arnold Frances |
Director |
• • – |
2020-05-11 |
4 |
AS |
$309.11 |
$464,592 |
D/D |
(1,503) |
9,954 |
|
-16% |
|
| Flatley Jay T |
Director |
• • – |
2020-05-05 |
4 |
AS |
$310.37 |
$931,110 |
D/D |
(3,000) |
245,970 |
|
14% |
|
| Desouza Francis A |
President and CEO |
• • – |
2020-05-01 |
4 |
AS |
$305.41 |
$925,819 |
D/D |
(3,000) |
84,158 |
|
14% |
|
| Dadswell Charles |
SVP & General Counsel |
• • – |
2020-05-01 |
4 |
AS |
$317.16 |
$38,376 |
D/D |
(121) |
9,841 |
|
14% |
|
| Van Oene Mark |
SVP Chief Commercial Officer |
• • – |
2020-05-01 |
4 |
AS |
$316.82 |
$198,016 |
D/D |
(625) |
20,130 |
|
14% |
|
| Flatley Jay T |
Director |
• • – |
2020-04-21 |
4 |
AS |
$310.77 |
$932,310 |
D/D |
(3,000) |
248,970 |
|
15% |
|
| Samad Samer Abdul |
SVP and CFO |
• • – |
2020-04-20 |
4 |
AS |
$320.02 |
$433,947 |
D/D |
(1,356) |
6,592 |
|
10% |
|
| Samad Samer Abdul |
SVP and CFO |
• • – |
2020-04-16 |
4 |
AS |
$300.00 |
$509,100 |
D/D |
(1,697) |
7,948 |
|
19% |
|
| Van Oene Mark |
SVP Chief Commercial Officer |
• • – |
2020-04-16 |
4 |
AS |
$300.22 |
$375,275 |
D/D |
(1,250) |
20,755 |
|
19% |
|
| Febbo Phillip G. |
SVP Chief Medical Officer |
• • – |
2020-04-16 |
4 |
AS |
$300.00 |
$51,900 |
D/D |
(173) |
2,490 |
|
19% |
|
| Samad Samer Abdul |
SVP and CFO |
• • – |
2020-04-14 |
4 |
AS |
$292.54 |
$72,842 |
D/D |
(249) |
9,645 |
|
23% |
|
| Flatley Jay T |
Director |
• • – |
2020-04-07 |
4 |
AS |
$284.63 |
$569,260 |
D/D |
(2,000) |
251,970 |
|
26% |
|
| Desouza Francis A |
President and CEO |
• • – |
2020-04-06 |
4 |
AS |
$275.00 |
$825,000 |
D/D |
(3,000) |
87,158 |
|
25% |
|
| Febbo Phillip G. |
SVP Chief Medical Officer |
• • – |
2020-04-05 |
4 |
D |
$278.01 |
$25,577 |
D/D |
(92) |
2,663 |
|
- |
|
| Dadswell Charles |
SVP & General Counsel |
• • – |
2020-04-01 |
4 |
AS |
$265.92 |
$32,176 |
D/D |
(121) |
9,962 |
|
24% |
|
| Hoyt Aimee L |
SVP, Chief People Officer |
• • – |
2020-03-05 |
4 |
AS |
$273.95 |
$114,237 |
D/D |
(417) |
3,689 |
|
39% |
|
| Flatley Jay T |
Director |
• • – |
2020-03-03 |
4 |
AS |
$277.40 |
$554,800 |
D/D |
(2,000) |
256,970 |
|
35% |
|
| Desouza Francis A |
President and CEO |
• • – |
2020-03-02 |
4 |
AS |
$275.00 |
$825,000 |
D/D |
(3,000) |
90,158 |
|
33% |
|
| Dadswell Charles |
SVP & General Counsel |
• • – |
2020-03-02 |
4 |
AS |
$268.02 |
$451,882 |
D/D |
(1,686) |
10,083 |
|
33% |
|
| Flatley Jay T |
Director |
• • – |
2020-02-18 |
4 |
AS |
$299.00 |
$897,000 |
D/D |
(3,000) |
255,970 |
|
20% |
|
| Ostadan Omead |
SVP Mktg, Prod & Strat Plan |
• • – |
2020-02-18 |
4 |
AS |
$298.10 |
$537,959 |
D/D |
(1,800) |
19,312 |
|
20% |
|
3466 Records found
|
|
Page 16 of 139 |
|
|
3.39 (2.96%) 
